Overcoming asset transfer challenges during a merger and acquisition (M&A)

In this video, Parexel’s Paul Bridges speaks with Phil Smith about how pharma and biotech can overcome common operational challenges and key considerations for a more successful asset transfer.

Return to Insights Center

Related Insights

Blog

Focusing on value drivers to reduce risk in early-stage drug development

Jan 6, 2025

Playbook

Early-phase development strategies for navigating regulatory complexity in the EU

Apr 29, 2024

Article

8 things you need to know about eCTDs in China

Jul 1, 2022

Blog

Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial

Nov 19, 2021

Webinar

Assessing appropriate use of ECAs in clinical trials

May 28, 2023

Playbook

What emerging trends in the FDA’s most coveted designations might tell us

Feb 8, 2024

Playbook

Streamlining development in the EU: Strategies for smoother CTA submissions

Feb 27, 2025

Article

How a joined-up development strategy pays off for early-stage biotechs

May 19, 2021

Webinar

Accelerated Early Phase Decision-Making – Insider Insights to Speed Development

Jan 7, 2025

Article

Near-term strategies for biotech drug developers facing shifting healthcare dynamics

Feb 14, 2024

Article

Expedited Pathways Comparisons - US EU CHN

Oct 19, 2021

Blog

Overcoming risks in Phase 3 trials to accelerate time to market

Jan 22, 2025

Related Insights

Blog

Focusing on value drivers to reduce risk in early-stage drug development

Jan 6, 2025

Playbook

Early-phase development strategies for navigating regulatory complexity in the EU

Apr 29, 2024

Article

8 things you need to know about eCTDs in China

Jul 1, 2022

Blog

Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial

Nov 19, 2021

Webinar

Assessing appropriate use of ECAs in clinical trials

May 28, 2023

Playbook

What emerging trends in the FDA’s most coveted designations might tell us

Feb 8, 2024

Show more